Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-11-09 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思首次公开发行网下配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO). It details the number of shares becoming freely tradable after the lock-up period, the dates involved, and references regulatory approvals and previous announcements. The document is relatively short (2231 characters) and focuses on the specifics of share circulation rather than presenting financial statements or detailed financial performance. It is not a full financial report, earnings release, or management discussion. It is a formal announcement about share listing and circulation, fitting the category of Share Issue/Capital Change (SHA).
2023-11-09 Chinese
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司首次公开发行网下配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from the sponsor (中信证券股份有限公司) regarding the listing and circulation of restricted shares from the initial public offering (IPO) of 杭州安杰思医学科技股份有限公司. It discusses the unlocking and circulation of restricted shares, the compliance with regulatory requirements, and the sponsor's confirmation that the shareholders have fulfilled their commitments. The document references regulatory rules and specific dates related to the IPO and share circulation but does not contain financial statements or detailed financial data. It is a formal verification or opinion related to share listing and circulation rather than a financial report or announcement of voting results. Given the nature of the document as a verification opinion on share circulation post-IPO, it fits best under Regulatory Filings (RNS) as it is a compliance-related regulatory announcement that does not fit other specific categories like capital changes or voting results.
2023-11-09 Chinese
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of raised funds by Hangzhou Anjiese Medical Technology Co., Ltd. It discusses the replacement of self-raised funds previously invested in projects with the newly raised funds from the IPO. The document references regulatory guidelines, approval from the board and supervisory committee, independent directors' opinions, and an accountant's verification report. It is a formal verification and compliance report related to the use of IPO proceeds and fund management, not a financial report like an annual or interim report. It is also not a simple announcement or a certification letter but a detailed verification opinion. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance and verification filing related to fundraising and fund usage, but not a direct capital/financing update or earnings release. The document length is 4025 characters, which is substantial but not a full financial report. Therefore, the best classification is Regulatory Filings (RNS).
2023-10-19 Chinese
安杰思关于召开2023年第三季度业绩说明会的公告
Call Transcript Classification · 90% confidence The document is an announcement about a scheduled investor meeting to discuss the company's third quarter 2023 financial results. It specifies the date, time, location, and format of the meeting, and invites investors to participate and ask questions. The document does not contain actual financial statements or detailed financial analysis but rather informs about the upcoming earnings call or performance explanation session. This matches the characteristics of a Call Transcript (CT) announcement or an Earnings Release (ER) announcement. However, since it is about an earnings explanation meeting (业绩说明会) and not the initial earnings release itself, and it is an announcement of the meeting rather than the transcript or report, the best fit is Call Transcript (CT) category, which includes earnings calls and Q&A sessions. The document length is short and it is an announcement of the meeting, not the transcript itself, but given the specific nature of the meeting (earnings explanation), CT is the closest category. Confidence is high due to clear references to the earnings explanation meeting and investor Q&A.
2023-10-19 Chinese
安杰思第二届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Hangzhou Anjiesi Medical Technology Co., Ltd. It discusses the approval of the company's 2023 third quarter report and several proposals related to the use of raised funds. The document references the actual 2023 third quarter report being published separately on the Shanghai Stock Exchange website and other media, indicating this document itself is not the report but an announcement of the Supervisory Board's meeting resolutions. The document length is short (1684 characters), and it mainly serves to announce meeting decisions and approvals rather than containing substantive financial data or the full quarterly report. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as it does not fit other more specific categories and is an official announcement of supervisory board resolutions related to financial reports and fund usage.
2023-10-19 Chinese
安杰思关于使用自有资金支付募投项目所需资金并以募集资金等额置换的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the use of its own funds to pay for investment projects and subsequently replacing these funds with raised capital. It details the approval process by the board and supervisory committee, references regulatory approvals, and includes opinions from independent directors, the supervisory board, and the sponsor. The document is about a specific financing and capital management activity related to the company's raised funds and their usage. It is not a full financial report, audit report, or earnings release, nor is it a general regulatory filing or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it concerns the company's capital structure and financing activities involving raised funds and their management.
2023-10-19 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.